Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of HIV‐1 virus‐like particles and determination of Gag stoichiometry for different production platforms

12 Apr 2021

Abstract excerpt

The importance of developing new vaccine technologies towards versatile platforms that can cope with global virus outbreaks has been evidenced with the most recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Virus-like particles (VLPs) are a highly immunogenic, safe, and robust approach that can be used to base several vaccine candidates on. Particularly, HIV-1 Gag VLPs is a flexible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Research and Treatment
Share to Monoclonal and Polyclonal Antibodies Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33844274
DOI: 10.1002/bit.27786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of HIV‐1 virus‐like particles and determination of Gag stoichiometry for different production platformsPMID 33844274Read ↗

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read ↗

Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approachesSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

N-terminal VP1 Truncations Favor T = 1 Norovirus-Like ParticlesSemantic proximity Read ↗

Recent Progress on the Versatility of Virus-Like ParticlesSemantic proximity Read ↗

N-terminal VP1 truncations favor <i>T</i> =1 norovirus-like particlesSemantic proximity Read ↗

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis systemSemantic proximity Read ↗

Competitive assembly resolves the stoichiometry of essential proteins in infectious HIV-1 virionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.